SCHEMBL3322503

SCHEMBL3322503

CC(C)(C)c1cc(O)c(O)cc1C(c1ccccc1)c1cc(O)c(O)cc1C(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.45
TSHR P16473 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP3A4 P08684 2/20 0.45
ALDH1A1 P00352 4/20 0.44
TDP1 Q9NUW8 2/20 0.44
ALOX15 P16050 5/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
ATP2A2 P16615 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ATP2A3 Q93084 1/20 0.43
TYR P14679 2/20 0.39
LMNA P02545 3/20 0.37
HSD17B10 Q99714 2/20 0.37
NR1I2 O75469 1/20 0.37
MIF P14174 1/20 0.37
HTT P42858 1/20 0.37
NFE2L2 Q16236 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9176167 0.91 ALOX15 (0.52) CYP2C9TSHRCYP1A2CYP2C19CYP3A4
SCHEMBL1238122 0.88 CYP2C9 (0.42) CYP2C9TSHRCYP1A2CYP2C19CYP3A4
SCHEMBL29874711 0.88 CYP2C9 (0.42) CYP2C9TSHRCYP1A2CYP2C19CYP3A4
SCHEMBL28808496 0.83 CYP2C9 (0.42) CYP2C9TSHRCYP1A2CYP2C19CYP3A4
SCHEMBL29482323 0.83 CYP2C9 (0.43) CYP2C9TSHRCYP1A2CYP2C19CYP3A4
SCHEMBL3979928 0.81 TYR (0.49) CYP2C9TSHRCYP1A2CYP2C19CYP3A4
SCHEMBL5372483 0.78 ALOX15 (0.56) CYP2C9TSHRCYP1A2CYP2C19CYP3A4
SCHEMBL28296891 0.77 TSHR (0.48) CYP2C9TSHRCYP1A2CYP2C19CYP3A4
SCHEMBL7759216 0.76 TYR (0.56) CYP2C9TSHRCYP1A2CYP2C19CYP3A4
SCHEMBL4060913 0.76 TYR (0.42) CYP2C9CYP1A2CYP2C19CYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2131423-B1 NEGATIVE ELECTRODE BASE MEMBER TOKYO OHKA KOGYO CO LTD (JP) 2017-11-15 EP disclosed
US-9105929-B2 Negative electrode base member TOKYO OHKA KOGYO CO., LTD. (JP) 2015-08-11 US disclosed
US-8927147-B2 Negative electrode base member KANTO GAKUIN SCHOOL CORPORATION (JP) 2015-01-06 US disclosed
EP-2472655-B1 Negative electrode base member TOKYO OHKA KOGYO CO LTD (JP) 2014-03-12 EP disclosed
US-8551651-B2 Secondary cell having negative electrode base member TOKYO OHKA KOGYO CO., LTD. (JP) 2013-10-08 US disclosed
US-20130252098-A1 NEGATIVE ELECTRODE BASE MEMBER KANTO GAKUIN UNIVERSITY SURFACE ENGINEERING RESEARCH INSTITUTE (JP) 2013-09-26 US disclosed
US-20130252099-A1 NEGATIVE ELECTRODE BASE MEMBER KANTO GAKUIN UNIVERSITY SURFACE ENGINEERING RESEARCH INSTITUTE (JP) 2013-09-26 US disclosed
EP-2472655-A1 Negative electrode base member Tokyo Ohka Kogyo Co., Ltd. (JP) 2012-07-04 EP disclosed
US-20100119939-A1 NEGATIVE ELECTRODE BASE MEMBER TOKYO OHKA KOGYO CO., LTD. (JP) 2010-05-13 US disclosed
EP-2131423-A1 NEGATIVE ELECTRODE BASE MEMBER Tokyo Ohka Kogyo Co., Ltd. (JP) 2009-12-09 EP disclosed
US-7534547-B2 Optically active compound and photosensitive resin composition OSAKA GAS COMPANY LIMITED (JP) 2009-05-19 US disclosed
EP-1375463-A1 OPTICALLY ACTIVE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION Kansai Research Institute, Inc. (JP) 2004-01-02 EP disclosed
US-20030211421-A1 Optically active compound and photosensitive resin composition KRI, INC. (JP) 2003-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030211421-A1 Optically active compound and photosensitive resin composition ARCN1, RAD51, PAM CYP2C9 1479/4885TSHR 4402/4885CYP1A2 1607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.